| Inducible apoptosis as a safety switch for adoptive cell therapy A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, ... New England Journal of Medicine 365 (18), 1673-1683, 2011 | 1636 | 2011 |
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma MA Pule, B Savoldo, GD Myers, C Rossig, HV Russell, G Dotti, MH Huls, ... Nature medicine 14 (11), 1264-1270, 2008 | 1375 | 2008 |
| Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma CU Louis, B Savoldo, G Dotti, M Pule, E Yvon, GD Myers, C Rossig, ... Blood, The Journal of the American Society of Hematology 118 (23), 6050-6056, 2011 | 1327 | 2011 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1244 | 2011 |
| Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15 Y Xu, M Zhang, CA Ramos, A Durett, E Liu, O Dakhova, H Liu, ... Blood, The Journal of the American Society of Hematology 123 (24), 3750-3759, 2014 | 779 | 2014 |
| Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes I Caruana, B Savoldo, V Hoyos, G Weber, H Liu, ES Kim, MM Ittmann, ... Nature medicine 21 (5), 524-529, 2015 | 730 | 2015 |
| Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, ... Leukemia 32 (2), 520-531, 2018 | 681 | 2018 |
| Design and development of therapies using chimeric antigen receptor‐expressing T cells G Dotti, S Gottschalk, B Savoldo, MK Brenner Immunological reviews 257 (1), 107-126, 2014 | 681 | 2014 |
| Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, ... Leukemia 24 (6), 1160-1170, 2010 | 638 | 2010 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 603 | 2013 |
| T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ... Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009 | 595 | 2009 |
| CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, ... Molecular therapy 25 (9), 2214-2224, 2017 | 485 | 2017 |
| CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma M Casucci, B Nicolis di Robilant, L Falcone, B Camisa, M Norelli, ... Blood, The Journal of the American Society of Hematology 122 (20), 3461-3472, 2013 | 387 | 2013 |
| Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes CA Ramos, B Ballard, H Zhang, O Dakhova, AP Gee, Z Mei, M Bilgi, ... The Journal of clinical investigation 127 (9), 3462-3471, 2017 | 385 | 2017 |
| Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells H Du, K Hirabayashi, S Ahn, NP Kren, SA Montgomery, X Wang, ... Cancer cell 35 (2), 221-237. e8, 2019 | 354 | 2019 |
| T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells J Vera, B Savoldo, S Vigouroux, E Biagi, M Pule, C Rossig, J Wu, ... Blood 108 (12), 3890-3897, 2006 | 340 | 2006 |
| Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors N Nishio, I Diaconu, H Liu, V Cerullo, I Caruana, V Hoyos, ... Cancer research 74 (18), 5195-5205, 2014 | 332 | 2014 |
| Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs S Ninomiya, N Narala, L Huye, S Yagyu, B Savoldo, G Dotti, HE Heslop, ... Blood, The Journal of the American Society of Hematology 125 (25), 3905-3916, 2015 | 321 | 2015 |
| Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma CA Ramos, NS Grover, AW Beaven, PD Lulla, MF Wu, A Ivanova, T Wang, ... Journal of clinical oncology 38 (32), 3794-3804, 2020 | 318 | 2020 |
| Clinical responses with T lymphocytes targeting malignancy-associated κ light chains CA Ramos, B Savoldo, V Torrano, B Ballard, H Zhang, O Dakhova, E Liu, ... The Journal of clinical investigation 126 (7), 2588-2596, 2016 | 308 | 2016 |
